CEO Total Pay
$8.2M
FY2021 Summary Compensation, near median
FY2021 SEC EDGAR DEF 14A
Global Blood Therapeutics, Inc. CEO pay ratio
The CEO earned $8.2M in FY2021 against median worker pay of $174,326 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2022-04-28
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2021
Data updated August 2026
Subscribe to Global Blood Therapeutics, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
47:1
Below Average (Scale: 0–1000:1)
CEO pay
$8.2M
Median worker
$174,326
Latest filing FY2021. This company's newest DEF 14A on file is for FY2021, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Global Blood Therapeutics, Inc. reported a 47:1 CEO-to-worker pay ratio in FY2021 - above the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 47:1
- FY2021 disclosed
- CEO total
- $8.2M
- Summary Compensation Table total
- Median worker
- $174,326
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2021
A component-level pay breakdown is not reported in Global Blood Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
47:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$8.2M
Companies in Industry
168
vs. Industry Median
Above
Global Blood Therapeutics, Inc.: MODEST · HEAVY pay ratio
Global Blood Therapeutics, Inc. disclosed 47:1 CEO-to-worker pay and $8.2M CEO total in FY2021. the CEO earned 47× the median employee ($174,326) in FY2021.
Median employee $174,326 (ELITE-MED); MODEST · HEAVY stamps put about 47 median-wage years per CEO year.
Pay Ratio
47:1
Below typical
What FY2021 shows for Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. disclosed 47:1 CEO-to-worker pay and $8.2M CEO total in FY2021. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Global Blood Therapeutics, Inc.'s $8.2M CEO total is above the $7.9M industry median CEO pay.
Global Blood Therapeutics, Inc. stamps MODEST · HEAVY · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2021
- Total Compensation
- $8.2M
- Median Employee Pay
- $174,326
- Pay Ratio
- 47:1
- Filing Date
- 2022-04-28
Company Info
- CIK
- 1629137
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 1629137, FY2021. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Global Blood Therapeutics, Inc. disclosed 47:1 CEO-to-worker pay and $8.2M CEO total in FY2021.
Read with Global Blood Therapeutics, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.
National Instruments Corp · HEAVY
ABS(ceo_total_comp) peer at $8.2M (Δ $17K lighter vs Global Blood Therapeutics, Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Mersana Therapeutics, Inc. · HEAVY
ABS(ceo_total_comp) peer at $8.2M (Δ $22K lighter vs Global Blood Therapeutics, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Scotts Miracle-gro Co · HEAVY
ABS(ceo_total_comp) peer at $8.2M (Δ $23K lighter vs Global Blood Therapeutics, Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Marcus & Millichap, Inc. · HEAVY
ABS(ceo_total_comp) peer at $8.2M (Δ $31K heavier vs Global Blood Therapeutics, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Global Blood Therapeutics, Inc. stamps MODEST · HEAVY · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · MODEST
See where MODEST · HEAVY packages sit on the national leaderboard after reading Global Blood Therapeutics, Inc..
Ratio primer · MODEST
Global Blood Therapeutics, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Global Blood Therapeutics, Inc. (CIK 1629137), FY2021. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.